PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.
Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.
PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2025 class of the...
Dubai and Kyiv, August 12, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, today announces that Kyivstar, its digital operator in Ukraine, has successfully conducted a test of satellite and terrestrial network integration using Starlink Direct to Cell technology. This is the first field test of of Starlink Direct to Cell in eastern Europe.
– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT –
TORONTO and DALLAS, Aug. 11, 2025 /PRNewswire/ - Perimeter Medical Imaging AI,...
– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT –
TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI,...
The NVIDIA TAO 6.0 integration delivers advanced foundation models, fine-tuning capabilities, prompt‑based segmentation, and in‑context segmentationManufacturers benefit from enhanced tools for on-premises inferencing and...
Ad hoc announcement pursuant to Art. 53 LR
NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...